Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Lung Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Thoracic Neoplasm
Lung Neoplasm

Cancer Family

Lung Neoplasm

CI-CAN-00000221Explore in graph →

Non-malignant2,726 active trials51 approved drugs619 evidence items

NCIt: C3200
MeSH: D008175

Overview
Statistics
Survival
Genomics41
Variants & evidence619
Drugs128
Trials11603
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (483)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 376–400 of 483 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing.
· PLoS One · 2016 · PMID 27045755 · validated civic_curation pubmed
Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes.
· Lung · 2013 · PMID 23749122 · validated civic_curation pubmed
Effectiveness of EGFR-TKIs in a Patient with Lung Adenocarcinoma Harboring an EGFR-RAD51 Fusion.
· Oncologist · 2019 · PMID 31064887 · validated civic_curation pubmed
A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib.
· Invest New Drugs · 2016 · PMID 26892698 · validated civic_curation pubmed
Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.
· Cancer Discov · 2014 · PMID 24302556 · validated civic_curation pubmed
Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations.
· Mol Cancer Ther · 2021 · PMID 34625502 · validated civic_curation pubmed
Emerging a Novel VOPP1-EGFR Fusion Coexistent With T790M as an Acquired Resistance Mechanism to Prior Icotinib and Sensitive to Osimertinib in a Patient With EGFR L858R Lung Adenocarcinoma: A Case Report.
· Front Oncol · 2021 · PMID 35004270

Showing 376–400 of 483 publications

← Previous
1
…
15
16
17
…
20
Next →

· validated civic_curation

Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report.

· Proc Natl Acad Sci U S A · 2016 · PMID 26917690 · validated civic_curation pubmed

Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.

· JAMA Oncol · 2015 · PMID 26181354 · validated civic_curation pubmed

Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.

· Clin Lung Cancer · 2015 · PMID 25769807 · validated civic_curation pubmed

Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.

· Clin Cancer Res · 2009 · PMID 19147750 · validated civic_curation pubmed

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.

· Proc Natl Acad Sci U S A · 2008 · PMID 18227510 · validated civic_curation pubmed

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

· Sci Transl Med · 2010 · PMID 21160078 · validated civic_curation pubmed

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

· Nature · 2007 · PMID 17625570 · validated civic_curation pubmed

Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.

· EMBO Mol Med · 2016 · PMID 26758680 · validated civic_curation pubmed

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.

· Cancer Cell · 2006 · PMID 16730237 · validated civic_curation pubmed

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

· Science · 2004 · PMID 15118125 · validated civic_curation pubmed

The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.

· Cell · 2012 · PMID 22541434 · validated civic_curation pubmed

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

· Nat Med · 2008 · PMID 19029981 · validated civic_curation pubmed

FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.

· Clin Cancer Res · 2014 · PMID 24771645 · validated civic_curation pubmed

Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer.

· PLoS One · 2011 · PMID 21666749 · validated civic_curation pubmed

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

· Science · 2007 · PMID 17463250 · validated civic_curation pubmed

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

· Cancer Discov · 2012 · PMID 22961667 · validated civic_curation pubmed

Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules.

· Br J Cancer · 2012 · PMID 22333600 · validated civic_curation pubmed

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.

· Cell Rep · 2014 · PMID 25199829 · validated civic_curation pubmed